腹腔内注射贝伐珠单抗治疗结直肠癌患者恶性腹腔积液的疗效和安全性评价

目的探讨腹腔内注射贝伐珠单抗治疗恶性腹腔积液的近期疗效及安全性； 方法收集46例桂林医学院附属医院胃肠外科2010年3月至2014年5月伴有难以控制的恶性腹腔积液的晚期结直肠癌患者。检测其腹腔积液中VEGF含量；并利用单因素生存分析对比两组患者的预后。 结果对照组的血清VEGF平均值为（671.8±499.15）pg/mL，与治疗组［平均值为（665.19.19±499.15）pg/mL］相比差异无统计学意义。治疗组中，治疗前腹腔积液VEGF量的平均值为（1 225.11±609.71）pg/mL，无穿刺中位生存时间为6个月（1~21个月）。与对照组相比，治疗组的穿刺引流时间明显延长（t值=6.328，P<0.05）。治疗后，腹腔积液的VEGF量（317.69±172.14）pg/mL，与治疗前相比差异存在统计学意义。治疗后的血清VEGF平均值为（170.61±115.92）pg/mL，与治疗前差异具有统计学意义。在生存分析中，治疗组的预后明显好于对照组（P<0.05）。 结论对于一部分合适的患者，腹腔内注射贝伐珠单抗对于恶性腹腔积液的治疗可能是一种有效地、安全的治疗手段。

The short-term effect and safety of anti-malignant ascites treated with intraperitoneal injection of bevacizumab

ObjectiveTo investigate the short-term effect and safety of anti-malignant ascites treated with intraperitoneal injection of bevacizumab. Methods46 colorectal cancer patients with uncontrolled malignant ascites at the A?liated Hospital of Guilin Medical College from 2010 to 2014 were enrolled in this study. Investigate the VEGF value of malignant ascites and analyze the survival time of two groups. ResultsThe mean VEGF value of control group is 671.8±499.15 pg/mL, and has not statistically significant than treatment group (mean value: 1225.11±609.71 pg/mL). In treat group, the mean VEGF value is 1225.11±609.71 pg/mL before treatment. The median survival time of non-paracentesis is 6 months (1~21 months). In contrast with control group, the time of non-paracentesis is significantly longer in treatment group (6.328, P<0.05). After treatment, the mean VEGF value is 317.69±172.14 pg/mL in treatment group. There is statistically significant than control group. In survival analysis, treatment group shows signi?cantly better overall survival (OS) (P<0.05). ConclusionFor a part of appropriate patients, treated with intraperitoneal injection of bevacizumab is an effective and safety method.